Differences in exon expression and alternatively spliced genes in blood of multiple sclerosis compared to healthy control subjects

Journal of Neuroimmunology

Volumn 230, Issue 1-2, 2011, Pages 124-129

  Tian, Yingfang ^a   Apperson, Michelle L ^a,b   Ander, Bradley P ^a   Liu, Dazhi ^a   Stomova, Boryana S ^a   Jickling, Glen C ^a   Enriquez, Richelle ^c   Agius, Mark A ^a,b   Sharp, Frank R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Northern California Health Care System   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alternative splicing; Blood biomarker; Exon expression profiles; Gene expression profiling; Multiple sclerosis

Indexed keywords

ERYTHROPOIETIN; FORMYLMETHIONYLLEUCYLPHENYLALANINE; GROWTH HORMONE; PROLACTIN;

ADULT; ALTERNATIVE RNA SPLICING; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EXON; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; MALE; MICROARRAY ANALYSIS; MULTIPLE SCLEROSIS; NERVE FIBER; PREDICTION; PRIORITY JOURNAL; UPREGULATION;

ADULT; ALTERNATIVE SPLICING; CLUSTER ANALYSIS; EXONS; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRINCIPAL COMPONENT ANALYSIS; YOUNG ADULT;

EID: 78650975552     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.09.001     Document Type: Article

References (64)

1. Achiron A., Gurevich M. Peripheral blood gene expression signature mirrors central nervous system disease: the model of multiple sclerosis. Autoimmun. Rev. 2006, 5:517-522.
2. Achiron A., Gurevich M., Friedman N., Kaminski N., Mandel M. Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity. Ann. Neurol. 2004, 55:410-417.
3. Achiron A., Gurevich M., Magalashvili D., Kishner I., Dolev M., Mandel M. Understanding autoimmune mechanisms in multiple sclerosis using gene expression microarrays: treatment effect and cytokine-related pathways. Clin. Dev. Immunol. 2004, 11:299-305.
4. Achiron A., Feldman A., Mandel M., Gurevich M. Impaired expression of peripheral blood apoptotic-related gene transcripts in acute multiple sclerosis relapse. Ann. N.Y. Acad. Sci. 2007, 1107:155-167.
5. Achiron A., Gurevich M., Snir Y., Segal E., Mandel M. Zinc-ion binding and cytokine activity regulation pathways predicts outcome in relapsing-remitting multiple sclerosis. Clin. Exp. Immunol. 2007, 149:235-242.
6. Affymetrix, white paper. identifying and validating alternative splicing variants, http://www.affymetrix.com/products_services/arrays/specific/exon.affx.
7. Alcina A., Fedetz M., Ndagire D., Fernandez O., Leyva L., Guerrero M., Arnal C., Delgado C., Matesanz F. The T244I variant of the interleukin-7 receptor-alpha gene and multiple sclerosis. Tissue Antigens 2008, 72:158-161.
8. Arthur A.T., Armati P.J., Bye C., Heard R.N., Stewart G.J., Pollard J.D., Booth D.R. Genes implicated in multiple sclerosis pathogenesis from consilience of genotyping and expression profiles in relapse and remission. BMC Med. Genet. 2008, 9:17.
9. Baranzini S.E., Galwey N.W., Wang J., Khankhanian P., Lindberg R., Pelletier D., Wu W., Uitdehaag B.M., Kappos L., Polman C.H., Matthews P.M., Hauser S.L., Gibson R.A., Oksenberg J.R., Barnes M.R. Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum. Mol. Genet. 2009, 18:2078-2090.
10. Bemmo A., Benovoy D., Kwan T., Gaffney D.J., Jensen R.V., Majewski J. Gene expression and isoform variation analysis using Affymetrix Exon Arrays. BMC Genomics 2008, 9:529.
11. Black D.L. Mechanisms of alternative pre-messenger RNA splicing. Annu. Rev. Biochem. 2003, 72:291-336.
12. Bomprezzi R., Ringner M., Kim S., Bittner M.L., Khan J., Chen Y., Elkahloun A., Yu A., Bielekova B., Meltzer P.S., Martin R., McFarland H.F., Trent J.M. Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum. Mol. Genet. 2003, 12:2191-2199.
13. Booth D.R., Arthur A.T., Teutsch S.M., Bye C., Rubio J., Armati P.J., Pollard J.D., Heard R.N., Stewart G.J. Gene expression and genotyping studies implicate the interleukin 7 receptor in the pathogenesis of primary progressive multiple sclerosis. J. Mol. Med. 2005, 83:822-830.
14. Capello E., Voskuhl R.R., McFarland H.F., Raine C.S. Multiple sclerosis: re-expression of a developmental gene in chronic lesions correlates with remyelination. Ann. Neurol. 1997, 41:797-805.
15. Cuperlovic-Culf M., Belacel N., Culf A.S., Ouellette R.J. Microarray analysis of alternative splicing. OMICS 2006, 10:344-357.
16. D'Netto M.J., Ward H., Morrison K.M., Ramagopalan S.V., Dyment D.A., DeLuca G.C., Handunnetthi L., Sadovnick A.D., Ebers G.C. Risk alleles for multiple sclerosis in multiplex families. Neurology 2009, 72:1984-1988.
17. Dutta R., Trapp B.D. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 2007, 68:S22-S31. Discussion S43-54.
18. Faustino N.A., Cooper T.A. Pre-mRNA splicing and human disease. Genes Dev. 2003, 17:419-437.
19. Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis-the plaque and its pathogenesis. N. Engl. J. Med. 2006, 354:942-955.
20. Glatt S.J., Everall I.P., Kremen W.S., Corbeil J., Sasik R., Khanlou N., Han M., Liew C.C., Tsuang M.T. Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia. Proc. Natl. Acad. Sci. USA 2005, 102:15,533-15,538.
21. Goertsches R.H., Hecker M., Zettl U.K. Monitoring of multiple sclerosis immunotherapy: from single candidates to biomarker networks. J. Neurol. 2008, 255(Suppl 6):48-57.
22. Green A.J., Barcellos L.F., Rimmler J.B., Garcia M.E., Caillier S., Lincoln R.R., Bucher P., Pericak-Vance M.A., Haines J.L., Hauser S.L., Oksenberg J.R. Sequence variation in the transforming growth factor-beta1 (TGFB1) gene and multiple sclerosis susceptibility. J. Neuroimmunol. 2001, 116:116-124.
23. Gregg C. Pregnancy, prolactin and white matter regeneration. J. Neurol. Sci. 2009, 285:22-27.
24. Gregg C., Shikar V., Larsen P., Mak G., Chojnacki A., Yong V.W., Weiss S. White matter plasticity and enhanced remyelination in the maternal CNS. J. Neurosci. 2007, 27:1812-1823.
25. Gregory S.G., Schmidt S., Seth P., Oksenberg J.R., Hart J., Prokop A., Caillier S.J., Ban M., Goris A., Barcellos L.F., Lincoln R., McCauley J.L., Sawcer S.J., Compston D.A., Dubois B., Hauser S.L., Garcia-Blanco M.A., Pericak-Vance M.A., Haines J.L. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat. Genet. 2007, 39:1083-1091.
26. Hafler D.A., Compston A., Sawcer S., Lander E.S., Daly M.J., De Jager P.L., de Bakker P.I., Gabriel S.B., Mirel D.B., Ivinson A.J., Pericak-Vance M.A., Gregory S.G., Rioux J.D., McCauley J.L., Haines J.L., Barcellos L.F., Cree B., Oksenberg J.R., Hauser S.L. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 2007, 357:851-862.
27. Iglesias A.H., Camelo S., Hwang D., Villanueva R., Stephanopoulos G., Dangond F. Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells. J. Neuroimmunol. 2004, 150:163-177.
28. Kinter J., Zeis T., Schaeren-Wiemers N. RNA profiling of MS brain tissues. Int. MS J. 2008, 15:51-58.
29. Kishore S., Stamm S. The snoRNA HBII-52 regulates alternative splicing of the serotonin receptor 2C. Science 2006, 311:230-232.
30. Klein L., Klugmann M., Nave K.A., Tuohy V.K., Kyewski B. Shaping of the autoreactive T-cell repertoire by a splice variant of self protein expressed in thymic epithelial cells. Nat. Med. 2000, 6:56-61.
31. Kumral A., Baskin H., Yesilirmak D.C., Ergur B.U., Aykan S., Genc S., Genc K., Yilmaz O., Tugyan K., Giray O., Duman N., Ozkan H. Erythropoietin attenuates lipopolysaccharide-induced white matter injury in the neonatal rat brain. Neonatology 2007, 92:269-278.
32. Liu X., Leung S., Wang C., Tan Z., Wang J., Guo T.B., Fang L., Zhao Y., Wan B., Qin X., Lu L., Li R., Pan H., Song M., Liu A., Hong J., Lu H., Zhang J.Z. Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease. Nat. Med. 2010, 16:191-197.
33. Lundmark F., Duvefelt K., Hillert J. Genetic association analysis of the interleukin 7 gene (IL7) in multiple sclerosis. J. Neuroimmunol. 2007, 192:171-173.
34. Lundmark F., Duvefelt K., Iacobaeus E., Kockum I., Wallstrom E., Khademi M., Oturai A., Ryder L.P., Saarela J., Harbo H.F., Celius E.G., Salter H., Olsson T., Hillert J. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat. Genet. 2007, 39:1108-1113.
35. Lynch K.W., Weiss A. A CD45 polymorphism associated with multiple sclerosis disrupts an exonic splicing silencer. J. Biol. Chem. 2001, 276:24,341-24,347.
36. Matlin A.J., Clark F., Smith C.W. Understanding alternative splicing: towards a cellular code. Nat. Rev. Mol. Cell Biol. 2005, 6:386-398.
37. Mayne M., Moffatt T., Kong H., McLaren P.J., Fowke K.R., Becker K.G., Namaka M., Schenck A., Bardoni B., Bernstein C.N., Melanson M. CYFIP2 is highly abundant in CD4+ cells from multiple sclerosis patients and is involved in T cell adhesion. Eur. J. Immunol. 2004, 34:1217-1227.
38. McKay F.C., Swain L.I., Schibeci S.D., Rubio J.P., Kilpatrick T.J., Heard R.N., Stewart G.J., Booth D.R. Haplotypes of the interleukin 7 receptor alpha gene are correlated with altered expression in whole blood cells in multiple sclerosis. Genes Immun. 2008, 9:1-6.
39. Poljakovic Z., Zurak N., Brinar V., Korsic M., Basic S., Hajnsek S. Growth hormone and insulin growth factor-I levels in plasma and cerebrospinal fluid of patients with multiple sclerosis. Clin. Neurol. Neurosurg. 2006, 108:255-258.
40. Racke M.K. Immunopathogenesis of multiple sclerosis. Ann. Indian Acad. Neurol. 2009, 12:215-220.
41. Ramanathan M., Weinstock-Guttman B., Nguyen L.T., Badgett D., Miller C., Patrick K., Brownscheidle C., Jacobs L. In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects. J. Neuroimmunol. 2001, 116:213-219.
42. Rane, L., Vudattu, N., Bourcier, K., Graniar, E., Hillert, J., Seyfert, V., Maeurer, M.J., Alternative splicing of interleukin-7 (IL-7) and interleukin-7 receptor alpha (IL-7Ralpha) in peripheral blood from patients with multiple sclerosis (MS). J. Neuroimmunol. 222:82-86.
43. Rollins B., Martin M.V., Morgan L., Vawter M.P. Analysis of whole genome biomarker expression in blood and brain. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010, 153B:919-936.
44. Satoh J., Nakanishi M., Koike F., Miyake S., Yamamoto T., Kawai M., Kikuchi S., Nomura K., Yokoyama K., Ota K., Kanda T., Fukazawa T., Yamamura T. Microarray analysis identifies an aberrant expression of apoptosis and DNA damage-regulatory genes in multiple sclerosis. Neurobiol. Dis. 2005, 18:537-550.
45. Satoh J., Nakanishi M., Koike F., Onoue H., Aranami T., Yamamoto T., Kawai M., Kikuchi S., Nomura K., Yokoyama K., Ota K., Saito T., Ohta M., Miyake S., Kanda T., Fukazawa T., Yamamura T. T cell gene expression profiling identifies distinct subgroups of Japanese multiple sclerosis patients. J. Neuroimmunol. 2006, 174:108-118.
46. Savino C., Pedotti R., Baggi F., Ubiali F., Gallo B., Nava S., Bigini P., Barbera S., Fumagalli E., Mennini T., Vezzani A., Rizzi M., Coleman T., Cerami A., Brines M., Ghezzi P., Bianchi R. Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. J. Neuroimmunol. 2006, 172:27-37.
47. Schrijver H.M., Crusius J.B., Garcia-Gonzalez M.A., Polman C.H., Pena A.S., Barkhof F., Uitdehaag B.M. Gender-related association between the TGFB1+869 polymorphism and multiple sclerosis. J. Interferon Cytokine Res. 2004, 24:536-542.
48. Sharp F.R., Lit L., Xu H., Apperson M., Walker W., Wong B., Gilbert D.L., Hershey A., Glauser T.A. Genomics of brain and blood: progress and pitfalls. Epilepsia 2006, 47:1603-1607.
49. Sharp F.R., Xu H., Lit L., Walker W., Apperson M., Gilbert D.L., Glauser T.A., Wong B., Hershey A., Liu D.Z., Pinter J., Zhan X., Liu X., Ran R. The future of genomic profiling of neurological diseases using blood. Arch. Neurol. 2006, 63:1529-1536.
50. Shi Y., Feng Y., Kang J., Liu C., Li Z., Li D., Cao W., Qiu J., Guo Z., Bi E., Zang L., Lu C., Zhang J.Z., Pei G. Critical regulation of CD4+ T cell survival and autoimmunity by beta-arrestin 1. Nat. Immunol. 2007, 8:817-824.
51. Singh M.K., Scott T.F., LaFramboise W.A., Hu F.Z., Post J.C., Ehrlich G.D. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy. J. Neurol. Sci. 2007, 258:52-59.
52. Solis A.S., Shariat N., Patton J.G. Splicing fidelity, enhancers, and disease. Front. Biosci. 2008, 13:1926-1942.
53. Stamova B.S., Apperson M., Walker W.L., Tian Y., Xu H., Adamczy P., Zhan X., Liu D.Z., Ander B.P., Liao I.H., Gregg J.P., Turner R.J., Jickling G., Lit L., Sharp F.R. Identification and validation of suitable endogenous reference genes for gene expression studies in human peripheral blood. BMC Med. Genomics 2009, 2:49.
54. Storek J., Nash R.A., McSweeney P.A., Furst D.E., Sullivan K.M. Normal interleukin-7 (IL7) levels and normal IL7 response to CD4 T lymphopenia in patients with multiple sclerosis and systemic sclerosis. Clin. Immunol. 2006, 121:118-119.
55. Sullivan P.F., Fan C., Perou C.M. Evaluating the comparability of gene expression in blood and brain. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2006, 141B:261-268.
56. Tazi J., Bakkour N., Stamm S. Alternative splicing and disease. Biochim. Biophys. Acta 2009, 1792:14-26.
57. Theil M.M., Miyake S., Mizuno M., Tomi C., Croxford J.L., Hosoda H., Theil J., von Horsten S., Yokote H., Chiba A., Lin Y., Oki S., Akamizu T., Kangawa K., Yamamura T. Suppression of experimental autoimmune encephalomyelitis by ghrelin. J. Immunol. 2009, 183:2859-2866.
58. Tian Y., Green P.G., Stamova B., Hertz-Picciotto I., Pessah I.N., Hansen R., Yang X., Gregg J.P., Ashwood P., Jickling G., Van de Water J., Sharp F.R. Correlations of gene expression with blood lead levels in children with autism compared to typically developing controls. Neurotox. Res. 2009, Electronic publication ahead of print, 2009 Nov 17. doi:10.1007/s12640-009-9126-x http://www.ncbi.nlm.nih.gov/pubmed/19921347.
59. van Baarsen L.G., van der Pouw Kraan T.C., Kragt J.J., Baggen J.M., Rustenburg F., Hooper T., Meilof J.F., Fero M.J., Dijkstra C.D., Polman C.H., Verweij C.L. A subtype of multiple sclerosis defined by an activated immune defense program. Genes Immun. 2006, 7:522-531.
60. Walker W.L., Liao I.H., Gilbert D.L., Wong B., Pollard K.S., McCulloch C.E., Lit L., Sharp F.R. Empirical Bayes accomodation of batch-effects in microarray data using identical replicate reference samples: application to RNA expression profiling of blood from Duchenne muscular dystrophy patients. BMC Genomics 2008, 9:494.
61. Weinshenker B.G., Hebrink D., Kantarci O.H., Schaefer-Klein J., Atkinson E., Schaid D., McMurray C.M. Genetic variation in the transforming growth factor beta1 gene in multiple sclerosis. J. Neuroimmunol. 2001, 120:138-145.
62. Yang L., Anderson D.E., Baecher-Allan C., Hastings W.D., Bettelli E., Oukka M., Kuchroo V.K., Hafler D.A. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 2008, 454:350-352.
63. Yong V.W. Prospects of repair in multiple sclerosis. J. Neurol. Sci. 2009, 277(Suppl 1):S16-S18.
64. Zhang Z., Duvefelt K., Svensson F., Masterman T., Jonasdottir G., Salter H., Emahazion T., Hellgren D., Falk G., Olsson T., Hillert J., Anvret M. Two genes encoding immune-regulatory molecules (LAG3 and IL7R) confer susceptibility to multiple sclerosis. Genes Immun. 2005, 6:145-152.